BiotechTube
Home/Pipeline/In vivo CAR-T Therapy

In vivo CAR-T Therapy

Oncology (unspecified)

Pre-clinicalActive

Key Facts

Indication
Oncology (unspecified)
Phase
Pre-clinical
Status
Active
Company
Stylus Medicine

About Stylus Medicine

Stylus Medicine is a private, pre-clinical biotech founded in 2021, based in Cambridge, MA. The company is developing a novel platform centered on engineered recombinases delivered via targeted LNPs to enable precise, in vivo gene insertion, aiming to create 'off-the-shelf' CAR-T therapies and other genetic medicines. Backed by prominent venture capital and led by an experienced team, Stylus is targeting a significant market opportunity in oncology, autoimmune, and genetic diseases by addressing key limitations of current cell and gene therapies.

View full company profile

Therapeutic Areas

OncologyAutoimmune DiseasesGenetic Diseases

Other Oncology (unspecified) Drugs

DrugCompanyPhase
Oncology Vaccine ProgramCHAIN BiotechPre-clinical
ARX305NovoCodex BiopharmaceuticalsPhase 1
ARX788NovoCodex BiopharmaceuticalsPhase 1
Cancer Immunotherapy NanotherapeuticFlashpoint TherapeuticsPhase 1
GRWD5769Greywolf TherapeuticsPhase 1/2
Platform-derived Program(s)Immuto ScientificDiscovery/Pre-clinical
MBT Oncology ProgramIonic PharmaceuticalsPre-clinical
ISB 2301Ichnos Glenmark InnovationPreclinical
GRC 65327Ichnos Glenmark InnovationPreclinical
Platform-Derived PipelinePhinomicsDiscovery/Pre-clinical
Lead Small-Molecule InhibitorEris BiotechPre-clinical
Orotecan™Edison OncologyPhase 1/2a